¡¡
ÄúµÄλÖà : Ê×Ò³ >> ºÃÒëÀ´·­Ò빫˾
Ö×Áö´Ê»ã

adenocarcinoma ÏÙ¹ÜÉÏÆ¤: ÏÙ°©

adrenal cortical carcinoma ÉöÉÏÏÙÆ¤ÖÊ: ÉöÉÏÏÙÆ¤Öʰ©

American Joint Committee on Cancer Staging; AJCC ÃÀ¹ú°©Ö¢·ÖÆÚÁªºÏίԱ»á

angiosarcoma Ѫ¹ÜÄÚÆ¤: Ѫ¹ÜÈâÁö

basal cell carcinoma »ùµ×ϸ°û: »ùµ×ϸ°û°©

calcitonin ÒÖ¸ÆËØ

carcinoembryonic antigen; CEA °©Åß¿¹Ô­

carcinoma ¶ñÐÔÉÏÆ¤Ö×Áö

Carcinoma in situ ԭλ°©

catecholamine ¶ù²è·Ó°·

chondrosarcoma Èí¹Ç: Èí¹ÇÈâÁö

choriocarcinoma Ì¥ÅÌÉÏÆ¤: ÈÞëĤ°©

direct extension Ö±½ÓÂûÑÓ

dysgerminoma ¶ñÐÔÅßÌ¥Áö

Dysplasia 񓃜

fetoprotein; AFP Ì¥µ°°×

fibrosarcoma ÏËά×éÖ¯: ÏËάÈâÁö

FIGO: International Federation of Gynecology and Obstetrics ¹ú¼Ê¸¾²ú¿ÆÑ§ÁªÃË

glioma Éñ¾­½ºÏ¸°û: Éñ¾­½ºÏ¸°ûÁö

hematogenous metastasis ѪÐÐ×ªÒÆ

hepatocellular carcinoma; hepatoma ¸Îϸ°û: ¸Îϸ°û°©

histopathological grading ×éÖ¯²¡Àí·Ö»¯

human chorionic gonadotropin; HCG ÈËÀàÈÞëĤ´ÙÐÔÏÙËØ

immature teratoma È«ÄÜϸ°û: δ³ÉÊì»ûÌ¥Áö

International Union against Cancer; UICC ¹ú¼Ê·À°©ÁªÃË

Invasive carcinoma ÇÖÏ®°©

leiomyosarcoma ƽ»¬¼¡: ƽ»¬¼¡ÈâÁö

leukemia ÔìѪϸ°û: °×Ѫ²¡

liposarcoma Ö¬·¾×éÖ¯: Ö¬·¾ÈâÁö

lymphangiosarcoma Áܰ͹ÜÄÚÆ¤: Áܰ͹ÜÈâÁö

lymphatic metastasis ÁܰÍ×ªÒÆ

lymphoma ÀàÁܰÍ×éÖ¯: ÁܰÍÁö

malignant melanoma Éñ¾­ÍâÅß²ã: ¶ñÐÔºÚÉ«ËØÁö

malignant meningioma ÄÔĤ: ¶ñÐÔÄÔĤÁö

malignant mesothelioma ¼äƤ: ¶ñÐÔ¼äÆ¤Áö

malignant mixed tumor ÍÙÒºÏÙ: ¶ñÐÔ»ìºÏÁö

malignant peripheral nerve sheath tumor, malignant schwannoma Éñ¾­ÇÊ: ¶ñÐÔÖܱßÉñ¾­ÇÊÖ×Áö

malignant pheochromocytoma ÉöÉÏÏÙËèÖÊ: ¶ñÐÔÊȸõϸ°ûÁö

malignant phyllodes tumor Èé·¿: ¶ñÐÔÒ¶×´Áö

malignant teratoma ¶ñÐÔ»ûÌ¥Áö

metastasis Ô¶´¦×ªÒÆ

Microinvasive carcinoma ΢ÇÖÏ®°©

mild dysplasia Çá¶ÈÒìÉú

moderate dysplasia ÖжÈÒìÉú

moderately differentiated Öжȷֻ¯

myeloma ½¬Ï¸°û: ¹ÇËèÁö

neuroblastoma Éñ¾­½Úϸ°û: Éñ¾­Ä¸Ï¸°ûÁö

neuroblastoma Éñ¾­Ä¸Ï¸°ûÁö

neuron-specific enolase; NSE Éñ¾­ÌØÒìÐÔÏ©´¼

node Áܰͽá

oma Á¼ÐÔÖ×Áö

osteosarcoma Ó²¹Ç: ¹ÇÈâÁö

poorly differentiated ·Ö»¯²»Á¼

prostate-specific antigen; PSA ǰÁÐÏÙÌØÒìÐÔ¿¹Ô­

prostatic acid phosphatase; PAP ǰÁÐÏÙËáÐÔÁ×Ëá

renal cell carcinoma ÉöÔàÉÏÆ¤: Éöϸ°û°©

rhabdomyosarcoma ºáÎÆ¼¡: ºáÎÆ¼¡ÈâÁö

sarcoma ¶ñÐÔ¼äÒ¶Ö×Áö

seminoma Éúֳϸ°û: ¾«Ï¸°ûÁö

severe dysplasia ÖØ¶ÈÒìÉú

squamous cell carcinoma ÁÛ×´ÉÏÆ¤: ÁÛ״ϸ°û°©

stage ÆÚ±ð

synovial sarcoma »¬Ä¤: »¬Ä¤ÈâÁö

thymic carcinoma ÐØÏÙÉÏÆ¤: ÐØÏÙ°©

transitional cell carcinoma ÃÚÄòµÀÉÏÆ¤: ¹ý¶Éϸ°û°©

tumor marker ÁÙ´²¼ìÑé: º¬Ö×Áö±ê¼Ç

undifferentiated δ·Ö»¯

well differentiated ·Ö»¯Á¼ºÃ

melanoma °©Ö¢ ºÚËØÁö

renaleelI Éöϸ°û°©

ova-rian Âѳ²°©

neuroblastoma Éñ¾­Ä¸Ï¸°ûÁö

cerebroma ÄÔÁö

lung cancer ·Î°©

hepatoma ;liver cancer ¸Î°©

breast carcinoma ÈéÏÙ°©

colon cancer ½á³¦°©

prostatic csarcinoma ǰÁÐÏÙ°©

mesothelioma ¼äƤÁö

leukemia ×Ôϸ°ûÁö

lymphoma ÁܰÍÈâÁö

multiple myeIoma ¶à·¢ÐÔ¹ÇËèÁö

SCID ÑÏÖØ¸´ºÏÃâÒßȱʧ֢

Cysticfibrosis ÄÒÐÔÏËά±äÐÔ

¼Ò×åÐÔÆ¢ÐÔÆ¶Ñª Gaucher's²¡

Familialhypercholesterolemia ¼Ò×åÐÔµ¨¹Ì´¼¹ý¶àÖ¢

HemophiIia ѪÓѲ¡

Purine nucleoside phosphorylase deficiency æÎÒ÷ºË¿àËáÁ×ËáËáȱ·¦Ö¢

Alpha- Iantitrypsin deficiency a-¿¹¼××´ÏÙËØÈ±·¦Ö¢

Fanconi sanemia Fanconi'sƶѪ֢

Hunter'ssyndrome ºàÌØÊÏ×ÛºÏÖ¢

ºÃÒëÀ´·­Ò빫˾ÊǸ߶˷­ÒëµÄÁìÅÜÕß,ÌṩӢµÂ·¨¶íÈյȶà¸öÓïÖֵĻ¥Òë·þÎñ,ÓÉÍ⼮ר¼ÒÒëÉó.
ÁªÏµÎÒÃÇ
  • µç»°: 025-86627350
  • 025-81795285
  • ´«Õæ: 025-86627350
  • Óʼþ: tiantianfanyi@yahoo.com.cn